Results 71 to 80 of about 268,869 (312)
Scientific Reports, 2017 Rivaroxaban is an oral direct factor Xa inhibitor approved for the treatment of stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation. Despite its efficacy, rivaroxaban therapy results in adverse effects and complications,
Dan Yang +5 more
doaj +1 more source
Targeting the angiotensin II type 2 receptor (AT2R) in colorectal liver metastases
Cancer Cell International, 2010 Background Blockade of the angiotensin (ANG) II type 1 receptor (AT1R) inhibits tumour growth in several cancers, including colorectal cancer (CRC) liver metastases.
Wen Shu-wen +3 more
doaj +1 more source
Pharmacological effects of raas blockade in ischemic nephropathy [PDF]
, 2016 Background: The management of ischemic nephropathy due to atherosclerotic renal artery stenosis has become increasingly conservative in the modern era, with current guidelines recommending optimized medical therapy as the initial step.
Barbano, Biagio +8 more
core +1 more source
Advanced Healthcare Materials, EarlyView.By fusing ACE2‐overexpressing membrane‐integrated liposome (MIL) with copper nanoparticles, the biomimetic Cu@MIL nanostructures were created that directly hijack the SARS‐CoV‐2 entry pathway. These particles combine potent virus‐targeting precision with intrinsic antiviral activity, achieving rapid neutralization and disinfection.
Pooja Aich +8 more
wiley +1 more source
Baseline characteristics and enrichment results from the SONAR trial [PDF]
, 2018 Aim: The SONAR trial uses an enrichment design based on the individual response to the selective endothelin receptor antagonist atrasentan on efficacy (the degree of the individual response in the urinary albumin‐to‐creatinine ratio [UACR]) and safety/
Andress, Dennis L. +15 more
core +3 more sources
Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction
Advanced Healthcare Materials, EarlyView.Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang +4 more
wiley +1 more source
Angiotensin Type 2 Receptor in Resistance Arteries of Type 2 Diabetic Hypertensive Patients [PDF]
Hypertension, 2007 The role of angiotensin type 2 receptor (AT 2 R) on vascular responses to angiotensin II in humans remains unclear. In this study we explored whether AT 2 R is expressed and functionally active on peripheral resistance arteries of hypertensive diabetic ...
SAVOIA, Carmine +3 more
openaire +3 more sources
Advanced Science, EarlyView.ABSTRACT Cancer‐associated fibroblasts (CAFs) are the predominant stromal components within the tumor microenvironment (TME), playing multifaceted roles in cancer progression through dynamic interactions with neoplastic and immune cells. Emerging evidence has revealed remarkable heterogeneity and plasticity of CAFs, which originate from diverse ...
Rujiao Liu +4 more
wiley +1 more source
Український Журнал Нефрології та Діалізу, 2014 Damage of renal function and dynamics of dyslipidemia in patients with type 2 diabetes mellitus with insufficient glycemic compensation under condition of correction of hypertension with angiotensin II receptor antagonists Introduction.
N.O. Pertseva
doaj +1 more source
Loss of angiotensin II receptor expression in dopamine neurons in Parkinson’s disease correlates with pathological progression and is accompanied by increases in Nox4- and 8-OH guanosine-related nucleic acid oxidation and caspase-3 activation [PDF]
, 2015 In rodent models of Parkinsons disease (PD), dopamine neuron loss is accompanied by increased expression of angiotensin II (AngII), its type 1 receptor (AT1), and NADPH oxidase (Nox) in the nigral dopamine neurons and microglia.
Aboud, O +6 more
core +2 more sources